Disclosed are methods and compositions for modulating adiposity-related conditions, which utilize inhibitors of phospholipase A2, and more particularly phospholipase A2 Group IIa (PLA2G2A). Representative adiposity-related conditions include obesity, type II diabetes, adipose inflammation, metabolic dysfunction, cardiovascular diseases and more generally, metabolic syndrome.
揭示了一种调节与
脂肪相关疾病的方法和组合物,利用
磷脂酶A2的
抑制剂,尤其是
磷脂酶A2第IIa组(P
LA2G2A)。代表性的与
脂肪相关疾病包括肥胖、2型糖尿病、
脂肪炎症、代谢功能障碍、心血管疾病以及更一般的代谢综合征。